Gilead starts Phase II lung cancer study of NX 211

GILD began U.S. Phase II testing of its NX 211 liposomal formulation of lurtotecan topoisomerase inhibitor in up to 87 patients with recurrent small cell lung cancer. The open-label trial will measure...